DeepMatter has announced the appointment of Bryn Roberts to its board of directors as a non-executive director from August 1.
The Glasgow-based digital chemistry developer hired Roberts to help expand the business into Europe, while meeting the needs of the pharmaceutical industry.
Roberts is currently senior vice president (SVP) and global head of data services at Swiss multinational healthcare company Roche Information Solutions, where he spent more than 15 years working.
He was recently the global head of operations, pharmaceutical research and early development for the company before his current roles.
As a member of the pharmaceutical research and early development leadership team he led innovation in disciplines such as data science and laboratory automation, including diverse applications of digital and artificial intelligence (AI) technologies.
Roberts oversaw the development and operation of Roche’s research and development innovation centres, including new state-of-the-art laboratories in Basel, Zurich, Munich and Shanghai.
He is a fellow at the University of Oxford, an associated faculty member with the University of Frankfurt Big Data Lab, lectures in medical informatics at the University of Applied Sciences, Switzerland and sits on a number of advisory boards.
Roberts has previously been recognised in the FierceBiotech IT list of Top 10 Biotech Techies and the Top 50 Big Data Influencers in Precision Medicine by the Big Data Leaders Forum.
Karen Bach, non-executive chair of DeepMatter Group, commented: "Bryn is a perfect fit for DeepMatter where we enable scientists to use data to discover and develop medicines that transform patients’ lives, reliably and cost effectively. His expertise will be invaluable as we continue in our goal of integrating chemistry with technology by building and commercialising powerful data platforms.”
Bryn Roberts, SVP and global head of data services at Roche, added: “My career goal is to drive and enable the delivery of innovative healthcare solutions that address a significant unmet need. The value of data captured directly in the lab via DeepMatter and the insights the industry can extract from them will spur further innovation.”
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free .
